nOPV2 + bOPV + IPV

This is a combination immunization regimen consisting of three polio vaccines: - **nOPV2 (novel oral poliovirus vaccine type 2):** A next-generation live attenuated oral polio vaccine specifically targeting type 2 poliovirus. It is a genetically modified version of the traditional monovalent OPV type 2 (mOPV2), designed to be more genetically stable and less likely to revert to neurovirulence or seed new outbreaks of circulating vaccine-derived poliovirus type 2 (cVDPV2). nOPV2 is primarily used for outbreak response and not for routine immunization[1][4][6]. - **bOPV (bivalent oral polio vaccine):** A live attenuated oral polio vaccine containing serotypes 1 and 3. It replaced trivalent OPV globally in April 2016 as part of the strategy to eliminate cVDPV associated with serotype 2[7][8]. - **IPV (inactivated poliovirus vaccine):** An injectable, inactivated whole-virus preparation that provides systemic immunity against all three types of wild and vaccine-derived polioviruses but does not induce strong mucosal immunity needed to halt transmission[4][7]. The combination aims to provide broad protection against all three types of polioviruses—using nOPV2 for targeted cVDPV2 outbreak control, bOPV for ongoing protection against types 1 and 3, and IPV for systemic immunity across all types. This approach may be used during outbreak responses or catch-up campaigns where rapid population-level immunity is required.

Other names

novel oral poliovirus vaccine type 2 + bivalent oral poliovirus vaccine + inactivated poliovirus vaccine